Apidra Purple Book BLA 021629

BLA number
021629
Proprietary names
Apidra
Proper names
insulin glulisine
Applicant
Sanofi-Aventis U.S. LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Apidrainsulin glulisine351(a)1,000UNITS/10ML (100UNITS/ML)InjectionIntravenous, SubcutaneousMulti-Dose VialRxLicensed2004-04-16
002Apidrainsulin glulisine351(a)300UNITS/3ML (100UNITS/ML)InjectionSubcutaneousMulti-Dose CartridgeDiscLicensed2005-12-20
003Apidrainsulin glulisine351(a)300UNITS/3ML (100UNITS/ML)InjectionSubcutaneousAutoinjectorRxLicensed2009-02-24

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-05-01U001Apidra351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U002Apidra351(a)DiscSanofi-Aventis U.S. LLC
2021-05-01U003Apidra351(a)RxSanofi-Aventis U.S. LLC
2021-04-01U002Apidra351(a)DiscSanofi-Aventis US LLC
2021-04-01U003Apidra351(a)RxSanofi-Aventis US LLC
2020-05-01R001Apidra351(a)RxSanofi-Aventis US LLC
2020-05-01R002Apidra351(a)DiscSanofi-Aventis US LLC
2020-05-01R003Apidra351(a)RxSanofi-Aventis US LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Apidra351(a)RxLicensed2004-04-16
2020-05-01002Apidra351(a)DiscLicensed2005-12-20
2020-05-01003Apidra351(a)RxLicensed2009-02-24